Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial-Reference-Cited by-同舟云学术

Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial

Published:2019-12-11 Issue:7 Volume:109 Page:918-929
ISSN:1861-0684
Container-title:Clinical Research in Cardiology
language:en
Short-container-title:Clin Res Cardiol

Author:

Takahashi Kuniaki,Kogame Norihiro,Tomaniak Mariusz,Chichareon Ply,Chang Chun-Chin,Modolo Rodrigo,Benit Edouard,Liebetrau Christoph,Janssens Luc,Ferrario Maurizio,Zurakowski Aleksander,van Geuns Robert Jan,Dominici Marcello,Huber Kurt,Buszman Pawel,Bolognese Leonardo,Tumscitz Carlo,Żmudka Krzysztof,Aminian Adel,Vrolix Mathias,Petrov Ivo,Wykrzykowska Joanna J.,de Winter Robbert J.,Hamm Christian,Steg Philippe Gabriel,Onuma Yoshinobu,Valgimigli Marco,Windecker Stephan,Vranckx Pascal,Garg Scot,Serruys Patrick W.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00392-019-01585-w.pdf

Reference22 articles.

1. Hordijk-Trion M, Lenzen M, Wijns W, de Jaegere P, Simoons ML, Scholte op Reimer WJ, Bertrand ME, Mercado N, Boersma E, Investigators E-C (2006) Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J 27(6):671–678. https://doi.org/10.1093/eurheartj/ehi731

2. Rothwell PM (2005) External validity of randomised controlled trials: “To whom do the results of this trial apply?”. Lancet 365(9453):82–93. https://doi.org/10.1016/S0140-6736(04)17670-8

3. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372(9644):1163–1173. https://doi.org/10.1016/S0140-6736(08)61244-1

4. de Boer SP, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen WJ, Serruys PW, Boersma E (2011) Evaluating the ‘all-comers’ design: a comparison of participants in two ‘all-comers’ PCI trials with non-participants. Eur Heart J 32(17):2161–2167. https://doi.org/10.1093/eurheartj/ehr126

5. Franzone A, Heg D, Raber L, Valgimigli M, Piccolo R, Zanchin T, Yamaji K, Stortecky S, Blochlinger S, Hunziker L, Praz F, Juni P, Windecker S, Pilgrim T (2016) External validity of the “all-comers” design: insights from the BIOSCIENCE trial. Clin Res Cardiol 105(9):744–754. https://doi.org/10.1007/s00392-016-0983-z

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial;European Journal of Internal Medicine;2024-08

2. Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes;Journal of the American Heart Association;2021-11-16

3. Recruitment Practices in Multicenter Randomized Clinical Trials: Time for a Relook;Journal of the American Heart Association;2021-11-16

4. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial;Clinical Research in Cardiology;2020-01-31